SCHEMBL7252279

SCHEMBL7252279

O=C(Nc1ccc(C2=C3C=CC(=N3)C(c3ccncc3)=C3C=CC(=N3)C(c3ccncc3)=C3C=CC(=N3)C(c3ccncc3)=C3C=CC2=N3)cc1)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 1/20 0.58
▸ TYK2 P29597 1/20 0.58
▸ POLB P06746 2/20 0.57
▸ STAT3 P40763 1/20 0.57
▸ SMN1; SMN2 Q16637 1/20 0.57
▸ HTT P42858 1/20 0.55
▸ PTPN1 P18031 4/20 0.54
▸ GAA P10253 1/20 0.51
▸ KCNK3 O14649 1/20 0.50
▸ KDM4E B2RXH2 4/20 0.48
▸ RAB9A P51151 2/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ BCAT2 O15382 1/20 0.48
▸ NAMPT P43490 2/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ ALDH1A1 P00352 2/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ PTPN2 P17706 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6448103 0.82 POLB (0.81) JAK2TYK2POLBSTAT3SMN1; SMN2
SCHEMBL7247633 0.82 DNMT1 (0.50) SMN1; SMN2PTPN1RAB9AKMT2ABCAT2
SCHEMBL7241026 0.82 TSHR (0.49) POLBSMN1; SMN2HTTGAAKDM4E
SCHEMBL14080751 0.78 NOTUM (0.52) SMN1; SMN2KDM4ERAB9AKMT2AALDH1A1
SCHEMBL27838898 0.78 NOTUM (0.52) SMN1; SMN2KDM4ERAB9AKMT2AALDH1A1
SCHEMBL164882 0.76 JAK2 (1.00) JAK2TYK2POLBSTAT3SMN1; SMN2
SCHEMBL23734986 0.74 GAA (0.85) JAK2TYK2POLBSTAT3SMN1; SMN2
SCHEMBL30828578 0.74 GAA (0.78) JAK2TYK2POLBSTAT3SMN1; SMN2
SCHEMBL30828573 0.74 GAA (0.78) JAK2TYK2POLBSTAT3SMN1; SMN2
SCHEMBL245938 0.74 MAPT (0.43) SMN1; SMN2GAAKDM4ERAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030105130-A1 Thiaporphyrin, selenaporphyrin, and carotenoid porphyrin compounds as c-myc and telomerase inhibitors NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-06-05 — — US disclosed
WO-2002078695-A1 THIAPORPHYRIN, SELENAPORPHYRIN, AND CAROTENOID PORPHYRIN COMPOUNDS AS C-MYC AND TELOMERASE INHIBITORS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-10-10 — — WO disclosed
US-5236914-A Antitumor agents, viricides CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 1993-08-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105130-A1 Thiaporphyrin, selenaporphyrin, and carotenoid porphyrin compounds as c-myc and telomerase inhibitors MYCBP, MYC, TERF2IP JAK2 3111/4885TYK2 4126/4885POLB 1448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback